Woodline Partners LP Achilles Therapeutics PLC Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.96 - $3.04 $19,827 - $30,752	-10,116 Reduced 4.16%	233,180 $588,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.23 $227,054 - $424,105	-81,091 Reduced 25.0%	243,296 $715,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $1.37 Million - $2.87 Million	324,387 New	324,387 $1.63 Million
Q3 2021 Nov 15, 2021	SELL	$5.81 - $9.93 $449,612 - $768,442	-77,386 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.79 - $17.86 $1.58 Million - $2.88 Million	-161,436 Reduced 67.6%	77,386 $758,000
Q1 2021 May 17, 2021	BUY	$16.55 - $16.55 $3.95 Million - $3.95 Million	238,822 New	238,822 $3.95 Million

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.